Every technology has Pros & Cons. Though Nanotech has enormous advantages and is widely applied in medical sciences but still a lot needs to be done regarding safety of nanomaterials inside human body.
the main problem in treating the AD is related to what exactly is the cause of AD (it seems the amyloid plaques and the related neuron damage are rather a symptom than the cause). Knowing the cause would allow to identify the right target to tackle by the therapy.
A lot of papers has been published and a couple of USD billions spent, yet so far all amyloid targeted treatments spectacularly failed in humans, though they were successful in the mouse model. There is even a saying that if you plan to get Alzheimer's you should become a mouse first.
The other problem is finding a suitable diagnostic method to allow for early enough detection of the disease to allow for prevention or early enough treatment, essentially before the damage is done. And it seems that by the time the amyloid plaques are present the damage has already been done. Again, no suitable set of biomarkers or other early indicators of the disease seems to be available.
Once the treatment modality is established, nanotechnology could be used to construct delivery vehicles to carry the drugs across the BBB, or to create sustained release or on demand release dosage forms. Analogously, once a set of biomarkers is developed, nanotechnology can be used to create the diagnostic tools.
As for me, I take all reports on nanotechnology based dosage forms with a (large) pinch of salt. This is because the "cargo carrying capacity" of the resulting delivery system seems never to be considered properly. To give you an example, liposomes can usually be loaded with just a few percent of the drug. This results in dosing unrealistic volumes of the drug liposomal solution should the daily dosage of the drug be anything more than a few milligrams per person.